Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AC 0682

Next Previous
X
Search
Drug Profile

AC 0682

Alternative Names: AC-0682; AC682

Latest Information Update: 24 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Accutar Biotechnology
  • Class Antineoplastics
  • Mechanism of Action Estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HER2 negative breast cancer

Most Recent Events

  • 11 Apr 2024 Accutar Biotechnology terminates phase I trial HER2 negative breast cancer (Late-stage disease, Metastatic disease) in USA since the sponsor's development strategy was adjusted(PO) (NCT05080842)
  • 28 Sep 2023 Accutar Biotechnology terminates a phase I trial for HER2 negative breast cancer (Late stage disease, Metastatic disease, Second line therapy or greater) in China (PO), since the sponsor's development strategy was adjusted (NCT05489679)
  • 12 Oct 2022 prior to Oct 2022, Phase-I clinical trials in HER2 negative breast cancer (Metastatic disease, Late-stage disease, Second line therapy or greater) in China (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top